The Motley Fool

Here’s my verdict on the Oxford Nanopore share price!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Arrowings ascending on a chalkboard
Image source: Getty Images.

Oxford Nanopore (LSE:ONT) shares debuted on the London Stock Exchange last Thursday via an initial public offering (IPO). The Oxford Nanopore share price soared immediately. Reviewing the IPO and what I have learnt about the company, should I consider buying the shares for my portfolio?

Successful IPO

Established in 2005 out of Oxford University, Oxford Nanopore has expanded rapidly with offices throughout the world. Its main focus is DNA and RNA molecule technology. These form the genetic makeup of organisms. There are lots of applications for such technology including healthcare and medicine, crop science, and scientific research too. With the technology being applicable to many different sectors, it could be very lucrative. Oxford also produces rapid Covid-19 tests.

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

The Oxford Nanopore share price debuted at 425p per share on Thursday. By the time trading opened on Friday, shares were trading close to 50% higher, for 626p per share. By the end of the close on Friday, shares fell back slightly to 615p per share. The IPO actually excluded retail investors initially with only financial institutions able to purchase stock. This has since changed with shares now available to retail investors too. As I write, shares are trading for 577p per share.

I would consider this a successful IPO. The spike in the Oxford Nanopore share price will only boost the financials and profile of this burgeoning firm.

Revenues increase, losses reported

With a successful IPO under its belt, let’s take a look at Oxford Nanopore’s financials. Although technology is hard to create, making it profitable is even harder in my opinion.

Reviewing Oxford Nanopore’s recent financials that are available, I saw that revenue doubled from 2019 to 2020. This rose from £52m to £113.9m. I believe the primary factor behind this revenue hike was the award of government contracts for Covid-19 testing technology and application.

Despite recording increased revenue, the firm was loss-making in 2019 and 2020. This can often be the case for firms that need to invest heavily in research and development (R&D). Some analysts note the company may not be profitable until at least 2026. This could affect the Oxford Nanopore share price and investor sentiment once the dust settles from the IPO.

I must note that the Oxford Nanopore share price at current levels is spiking as many other tech stocks do based on potential value and revenue in the future.

My verdict on the Oxford Nanopore share price

I have concerns about buying Oxford Nanopore shares. Firstly, it is loss-making, which I understand is sometimes part of the journey for tech firms in early stages. Still, I want to see a more solid financial standing before I consider investing. Consistent losses may also lead to liquidity issues as well. Secondly, competition could affect investor sentiment too. DNA/RNA sequencing is not a new area and others are also attempting to create the latest tech as well, such as American firm Illumina.

Right now I would not buy shares in Oxford Nanopore for my portfolio. I believe the firm is too early in its journey to show me tangible results and revenue streams for the future and the risks noted earlier put me off too. I would look at other tech stocks that could offer me better prospects of returns.

FREE REPORT: Why this £5 stock could be set to surge

Are you on the lookout for UK growth stocks?

If so, get this FREE no-strings report now.

While it’s available: you'll discover what we think is a top growth stock for the decade ahead.

And the performance of this company really is stunning.

In 2019, it returned £150million to shareholders through buybacks and dividends.

We believe its financial position is about as solid as anything we’ve seen.

  • Since 2016, annual revenues increased 31%
  • In March 2020, one of its senior directors LOADED UP on 25,000 shares – a position worth £90,259
  • Operating cash flow is up 47%. (Even its operating margins are rising every year!)

Quite simply, we believe it’s a fantastic Foolish growth pick.

What’s more, it deserves your attention today.

So please don’t wait another moment.

Get the full details on this £5 stock now – while your report is free.

Jabran Khan has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.